Activation of PI3K/AKT has been suggested to induce tamoxifen resistance in ER+ve breast cancer [37], and increased activity of the ERK1/2 pathway has been shown to involve tamoxifen resistance [38]. Here, MAPK3 is linked to breast cancer.